News >

Expert Reviews CLL Advances Presented at ASH

Danielle Bucco
Published: Thursday, Apr 05, 2018

Alan Skarbnik, MD
Alan Skarbnik, MD
The 2017 ASH Annual Meeting provided physicians with numerous updates for the treatment of patients with chronic lymphocytic leukemia (CLL), leaving experts to predict what regulatory advances could take place in the near future.

on Hematologic Malignancies, Skarbnik, staff physician, Department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, shared his insight on the latest updates in CLL presented at the 2017 ASH Annual Meeting.

OncLive®: What is the current state of CLL?

Skarbnik: Newer combinations are coming along improving response rates, survival rates, and PFS rates for patients. We are looking at the evidence suggesting the importance of minimal residual disease (MRD)-negativity in CLL. We can have long-term treatment-free intervals for some patients, but since the novel therapies need to be given continuously, we are looking to stop it earlier.

Can you speak to some of the combination data that were presented at ASH?

The biggest splash at the 2017 ASH Annual Meeting was the MURANO trial. It is a phase III trial for patients with relapsed CLL independent of cytogenetics and they must have had at least 1 chemotherapy-containing line of therapy to be enrolled in the trial. Patients were randomized to either BR, which is one of the standards of care for CLL, or venetoclax plus rituximab. BR was given in the usual fashion for 6 cycles; however, in the venetoclax/rituximab combination, rituximab was given for 6 months—starting after the ramp-up of venetoclax—but venetoclax had a finite therapy time of 2 years. Patients stayed on the drug for 2 years but if they progressed or had an unacceptable toxicity, they stopped sooner. This is different to how venetoclax has been approved, which is continuous until disease progression.

Finally, these patients stopped therapy after 2 years and 90% of patients who were on the venetoclax/rituximab arm have not received any additional therapy at this point. It is a very telling number and it shows that patients who need to be on therapy forever may stop. That may be an attractive approach for patients because many don't want to be on a pill for the rest of their lives. 

Ibrutinib (Imbruvica) has long-term data demonstrating its efficacy. What is the future role of ibrutinib as a single agent or in combination, and which patients are best able to receive it?

One of the downfalls of ibrutinib as a single agent is that although most patients respond to the drug, they don't achieve a complete response to the drug as monotherapy. There was a trial for patients with either high-risk or relapsed disease to either use ibrutinib as a single agent or ibrutinib plus rituximab. The goal was to see improvement in PFS and, although there was a slightly higher rate of CR in the rituximab-containing arm, there was no difference in PFS for those patients. 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication